ArticleTheranostics2014
Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release.
Article in Theranostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 219 citations in OpenAlex.
- Magnetothermally Responsive Mesoporous Silica Nanocarriers: Materials Design, Thermoresponsive Gates and Controlled Drug Release.Nanomaterials (Basel, Switzerland) · 2026Review
- Heptanuclear iron complex as a potential contrast agent for MRI.Magnetic resonance letters · 2026Article
- Magnetic hyperthermia-based therapies for cancer targeting: current progress and future perspectives.Medical oncology (Northwood, London, England) · 2025Review
- Nanotechnology for immuno-oncology.Nature cancer · 2025Review
- Sustained Drug Release from Dual-Responsive Hydrogels for Local Cancer Chemo-Photothermal Therapy.Macromolecular bioscience · 2025Article
- Current Trends and Advances in Nanoplatforms-Based Imaging for Cancer Diagnosis.Indian journal of microbiology · 2025Article
- Article
- Magnetic Hyperthermia in Glioblastoma Multiforme Treatment.International journal of molecular sciences · 2024Review
- Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib.International journal of hematology · 2024Article
- Multilayer Methacrylate-Based Wound Dressing as a Therapeutic Tool for Targeted Pain Relief.Materials (Basel, Switzerland) · 2023Article
- Study on Doxorubicin Loading on Differently Functionalized Iron Oxide Nanoparticles: Implications for Controlled Drug-Delivery Application.International journal of molecular sciences · 2023Article
- Synthesis of Biocompatible Superparamagnetic Iron Oxide Nanoparticles (SPION) under Different Microfluidic Regimes.ACS applied materials & interfaces · 2022Article
- Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review.Nanomaterials (Basel, Switzerland) · 2022Review
- Novel Strategy for Optimized Nanocatalytic Tumor Therapy: From an Updated View.Small science · 2022Article
- Controlled release of carnosine from poly(lactic-Nanoscale advances · 2022Article
- Smart nanomaterials for cancer diagnosis and treatment.Nano convergence · 2022Review
- Novel Methacrylate-Based Multilayer Nanofilms with Incorporated FePt-Based Nanoparticles and the Anticancer Drug 5-Fluorouracil for Skin Cancer Treatment.Pharmaceutics · 2022Article
- Smart Magnetic Nanocarriers for Multi-Stimuli On-Demand Drug Delivery.Nanomaterials (Basel, Switzerland) · 2022Article
- Multifunctional Iron Oxide Magnetic Nanoparticles for Biomedical Applications: A Review.Materials (Basel, Switzerland) · 2022Review
- Exploration of Site-Specific Drug Targeting-A Review on EPR-, Stimuli-, Chemical-, and Receptor-Based Approaches as Potential Drug Targeting Methods in Cancer Treatment.Journal of oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the synthesis of smart nanoparticles (NPs) that generate heat in response to an alternating current magnetic field (ACMF) and that sequentially release an anticancer drug (doxorubicin, DOX). We further study the in vivo therapeutic efficacy of the combination of magnetic hyperthermia (MHT) and chemotherapy using the smart NPs for the treatment of multiple myeloma. The smart NPs are composed of a polymer with a glass-transition temperature (T g) of 44°C, which contains clustered Fe3O4 NPs and DOX. The clustered Fe3O4 NPs produce heat when the ACMF is applied and rise above 44°C, which softens the polymer phase and leads to the release of DOX. The combination of MHT and chemotherapy using the smart NPs destroys cancer cells in the entire tumor and achieves a complete cure in one treatment without the recurrence of malignancy. Furthermore, the smart NPs have no significant toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.